

# Wnt/Ca<sup>2+</sup>/NFAT Signaling Maintains Survival of Ph<sup>+</sup> Leukemia Cells upon Inhibition of Bcr-Abl

Mark A. Gregory,<sup>1</sup> Tzu L. Phang,<sup>2</sup> Paolo Neviani,<sup>6</sup> Francesca Alvarez-Calderon,<sup>3</sup> Christopher A. Eide,<sup>7,8</sup> Thomas O'Hare,<sup>7,8</sup> Vadym Zaberezhnyy,<sup>1</sup> Richard T. Williams,<sup>9</sup> Brian J. Druker,<sup>7,8</sup> Danilo Perrotti,<sup>6</sup> and James DeGregori<sup>1,3,4,5,\*</sup>

<sup>1</sup>Department of Biochemistry and Molecular Genetics

<sup>2</sup>Division of Pulmonary Sciences and Critical Care Medicine

<sup>3</sup>Integrated Department of Immunology

<sup>4</sup>Program in Molecular Biology

<sup>5</sup>Department of Pediatrics

University of Colorado School of Medicine, Aurora, CO 80045, USA

<sup>6</sup>Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA

<sup>7</sup>Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR 97239, USA

<sup>8</sup>Howard Hughes Medical Institute, Portland, OR 97239, USA

<sup>9</sup>Department of Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA

\*Correspondence: james.degregori@ucdenver.edu

DOI 10.1016/j.ccr.2010.04.025

## SUMMARY

Although Bcr-Abl kinase inhibitors have proven effective in the treatment of chronic myeloid leukemia (CML), they generally fail to eradicate Bcr-Abl<sup>+</sup> leukemia cells. To identify genes whose inhibition sensitizes Bcr-Abl<sup>+</sup> leukemias to killing by Bcr-Abl inhibitors, we performed an RNAi-based synthetic lethal screen with imatinib mesylate in CML cells. This screen identified numerous components of a Wnt/Ca<sup>2+</sup>/NFAT signaling pathway. Antagonism of this pathway led to impaired NFAT activity, decreased cytokine production, and enhanced sensitivity to Bcr-Abl inhibition. Furthermore, NFAT inhibition with cyclosporin A facilitated leukemia cell elimination by the Bcr-Abl inhibitor dasatinib and markedly improved survival in a mouse model of Bcr-Abl<sup>+</sup> acute lymphoblastic leukemia (ALL). Targeting this pathway in combination with Bcr-Abl inhibition could improve treatment of Bcr-Abl<sup>+</sup> leukemias.

## INTRODUCTION


CML is a myeloproliferative disorder characterized by a t(9;22) translocation, which gives rise to a shortened chromosome 22, the Philadelphia chromosome (Ph). This translocation results in a fusion between the genes encoding the Abl tyrosine kinase and Bcr. The resultant protein, Bcr-Abl, has constitutive tyrosine kinase activity and is considered causative in the disease (Deininger et al., 2000). Ph is also found in 20%–30% of ALL and is associated with poor prognosis (Faderl et al., 2002). Bcr-Abl activates a number of downstream targets including Ras, PI3 kinase, NF- $\kappa$ B, and STAT5, resulting in cytokine-inde-

pendent growth, resistance to apoptosis, and altered cellular adhesion (Sattler and Griffin, 2003).

Imatinib mesylate is a tyrosine kinase inhibitor that blocks the activity of Bcr-Abl and induces remarkable hematological and cytogenetic responses in chronic phase CML patients (Deininger et al., 2005). Although imatinib is a highly effective treatment for CML, it is rarely curative. Cessation of imatinib therapy can result in relapse of the disease even in patients that show a complete response (Rousselot et al., 2007). Furthermore, a significant number of chronic phase patients on imatinib therapy eventually relapse (16% within 42 months; (Deininger et al., 2005). Relapse is often associated with mutation of Bcr-Abl. Another major

### Significance

The promise of targeted cancer therapies has generated much excitement with the success of Bcr-Abl inhibitors for treatment of chronic phase CML. However, targeted therapies for other cancers have typically failed to achieve durable responses. For example, patients with advanced phase CML and Bcr-Abl<sup>+</sup> ALL do not show long-term responses to Bcr-Abl inhibitors. The targeting of additional genes may be necessary to enhance the efficacy of Bcr-Abl inhibitors. The RNAi-based screen described here identified numerous components of a Wnt/Ca<sup>2+</sup>/NFAT pathway whose inhibition sensitizes leukemic cells to Bcr-Abl inhibitors. Pharmacological targeting of this pathway could improve the treatment of Bcr-Abl<sup>+</sup> leukemias. Our screen may also serve as a model for discovery of adjuvant targeted therapies for other forms of cancer.



**Figure 1. Knockdown of FZD-8 Sensitizes CML Cells to Imatinib and Impairs NFAT Activity**

(A) Diagrammatic representation of the Wnt/ $\text{Ca}^{2+}$ /NFAT pathway. Pathway details are described in the text.

(B) K562 CML cells were stably transduced with shRNAs (shA or shB) targeting FZD-8 or a negative control shRNA. Real-time PCR (qPCR) was performed on resultant cell lines to examine FZD-8 expression levels normalized to 18S ribosomal RNA.

(C) K562 cell lines were left untreated or treated with imatinib at 0.1  $\mu\text{M}$  for 72 hr, after which the cells were reseeded in the absence of drug and cultured for an additional 4 days. The number of viable cells (based on PI exclusion) was counted by flow cytometry at the indicated time points.

(D) K562 cell lines were infected with an adenoviral NFAT-luciferase reporter. After 32 hr, the cells were left untreated or treated with ionomycin at 1  $\mu\text{g}/\text{ml}$  for 16 hr after which the cells were harvested and luciferase activity was assayed. Error bars represent  $\pm$  SD. See also Figure S2.

concern is that advanced phase CML and  $\text{Ph}^+$  ALL are innately more refractory than chronic phase CML to imatinib therapy. Only 15% of patients in CML blast crisis and 29% of  $\text{Ph}^+$  ALL patients achieve a complete hematological response, and a majority of these relapse within a few months (Deininger et al., 2005; Ottmann et al., 2002). Advanced phase CML patients and those with  $\text{Ph}^+$  ALL also fail to achieve durable remissions with the more potent second-generation Bcr-Abl inhibitors nilotinib and dasatinib (Quintas-Cardama et al., 2007). These findings underscore the need to identify targets that will cooperate with Bcr-Abl inhibition to more effectively treat CML and  $\text{Ph}^+$  ALL and hopefully eradicate these diseases.

Wnt family members are secreted proteins that signal through the *frizzled* superfamily of G protein-coupled receptors. Activation of the canonical Wnt signaling pathway leads to nuclear accumulation of the Lef-Tcf transcriptional coactivator  $\beta$ -catenin (Cadigan and Liu, 2006). In addition, two noncanonical Wnt path-

ways have been identified that signal independently of  $\beta$ -catenin: the planar cell polarity pathway and the  $\text{Ca}^{2+}$ /NFAT pathway (Veeman et al., 2003). In the Wnt/ $\text{Ca}^{2+}$ /NFAT pathway (Figure 1A), Wnt5a-bound Frizzled (FZD), in association with a noncanonical coreceptor such as Ryk, acts through G proteins to activate phospholipase C (PLC) and phosphodiesterase (PDE) (Ahumada et al., 2002; Sheldahl et al., 2003; Slusarski et al., 1997). Activation of PLC initiates hydrolysis of membrane-bound lipid, generating two secondary messengers, diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3). DAG stimulates protein kinase C (PKC), whereas IP3 promotes the release of intracellular  $\text{Ca}^{2+}$ . Increased concentrations of  $\text{Ca}^{2+}$  lead to activation of the  $\text{Ca}^{2+}$ -sensitive proteins  $\text{Ca}^{2+}$ -calmodulin-dependent protein kinase II (CaMKII; Kuhl et al., 2000) and the  $\text{Ca}^{2+}$ -calmodulin-dependent protein phosphatase calcineurin and its target, the transcription factor NFAT (Saneyoshi et al., 2002). Dephosphorylation of NFAT by calcineurin promotes its

translocation to the nucleus where it can activate the transcription of cytokine genes such as interleukin-4 (IL-4; Hogan et al., 2003). A role for the Wnt/Ca<sup>2+</sup>/NFAT pathway in leukemia cells is unclear.

The purpose of this study was to identify pathways that can be targeted to more effectively eliminate Ph<sup>+</sup> leukemia cells in combination with Bcr-Abl inhibition.

## RESULTS

### RNAi-Based Screen Identifies Wnt/Ca<sup>2+</sup>/NFAT Pathway Genes as Synthetic Lethal with Imatinib

In order to identify genes and pathways whose inhibition sensitizes CML cells to killing by imatinib, we performed a large-scale RNAi-based synthetic lethal screen. A lentiviral shRNA library was utilized that contains 3–5 shRNAs per target gene for ~50,000 different human transcripts. This library was transduced into K562 CML cells and the cells were selected in puromycin for 2 weeks to obtain a pure population of transduced cells and allow for the exclusion of shRNAs that target essential genes. The transduced cells were either left untreated or treated with imatinib at 1  $\mu$ M for 72 hr, a dose that eliminated approximately 85% of the cells. The cells were cultured for an additional week, and total RNA was then isolated, reverse-transcribed, and the shRNA sequences were polymerase chain reaction (PCR) amplified and labeled with biotin. Biotin-labeled PCR products were used to probe Affymetrix microarrays to assess representation of individual shRNAs. Although few shRNAs provided resistance, a number of shRNAs were deleterious to K562 cells upon exposure to imatinib (see Figure S1A available online). Our screen identified 145 genes (Table S1) that met the following three criteria: (1) shRNAs targeting the gene were underrepresented > 6-fold in imatinib treated cells compared with untreated cells in  $\geq 2/3$  of comparisons; (2) the observed differences had a p value of < 0.05; and (3) at least two unique shRNAs per target gene were identified, minimizing identification of false positives due to off-target effects. We have dubbed these genes “SLIMs” (for synthetic lethal with imatinib mesylate). The SLIMs fall into functional categories that include cell attachment, inflammatory signaling, cell migration, hematological system development, and hematopoietic cell proliferation and differentiation (Figure S1B and Table S2).

Among the SLIMs, the Wnt receptor FZD-8 was identified by three different shRNAs, each underrepresented > 116-fold in imatinib-treated cells. FZD-8 is a poorly characterized Wnt receptor whose signaling in mammalian cells remains largely unstudied. Components of the canonical Wnt/ $\beta$ -catenin pathway signaling were not identified; however, isoforms of both CaMKII ( $\beta$ ) and PKC ( $\theta$ ), which are known to participate in the noncanonical Wnt/Ca<sup>2+</sup>/NFAT pathway, were identified. When the screen criteria were loosened to include genes that were identified by single shRNAs, canonical Wnt pathway components were still not found. Conversely, numerous potential components of the Wnt/Ca<sup>2+</sup>/NFAT signaling pathway were additionally identified (Table 1). These include the noncanonical ligand Wnt5a, FZD-2 (Ahumada et al., 2002), the noncanonical FZD coreceptor Ryk (Kim et al., 2008), p38 $\beta$  MAPK, PDE6C, and H, PLC $\beta$ , CaMKII $\gamma$  and its substrate RAR $\alpha$  (Si et al., 2007), calcineurin A ( $\alpha$  and  $\beta$ ), NFATc1, and its target genes IL-4 (Guo et al., 2008) and CCL23

(Shin et al., 2007). This list also includes several genes that, although not known to be involved in noncanonical Wnt signaling, are known or suspected to influence NFAT-dependent transcription: IL-7, RCAN1, NFATC2IP, Fra-1, EGR3, and PRMT8 (Boise et al., 1993; Gringhuis et al., 1997; Hodge et al., 1996; Liu et al., 2009; Mowen et al., 2004; Rengarajan et al., 2000). Thus, screening results suggest a role for Wnt/Ca<sup>2+</sup>/NFAT in maintaining CML survival in the face of Bcr-Abl inhibition.

### Inhibiting the Wnt/Ca<sup>2+</sup>/NFAT Pathway Sensitizes Ph<sup>+</sup> Leukemia Cells to Killing by Bcr-Abl Inhibitors

To verify that knockdown of the FZD-8 receptor sensitizes CML cells to imatinib, we stably transduced two different lentiviral constructs expressing shRNAs targeting FZD-8 (shA and shB) into K562 cells. Analysis of FZD-8 expression using real-time PCR revealed that shB significantly reduced FZD-8 expression (~50%) relative to a control non-targeting shRNA, whereas shA failed to significantly reduce expression (Figure 1B), and thus shA serves as an additional negative control. shB did not have a substantial impact on the proliferation rate of K562 cells (Figure S2A), indicating that FZD-8 knockdown does not affect cell viability in the absence of imatinib. For examining the consequences of imatinib treatment, these cell lines were exposed to 0.1  $\mu$ M imatinib for 72 hr and the number of viable cells, based on propidium iodide (PI) exclusion, was determined with flow cytometry. The cells were then reseeded in the absence of drug and viability was monitored over 7 days. Figure 1C shows that shB-expressing cells were severely sensitized to imatinib-mediated killing relative to untransduced and control cells. This translated into a dramatic effect on long-term viability: whereas the control cells recovered from imatinib treatment and were proliferating normally by day 7, the shB cells did not significantly recover. These results suggest that even partial FZD-8 knockdown can significantly potentiate the efficacy of imatinib in killing CML cells.

FZD-8 is a largely unstudied Wnt receptor whose role in activating noncanonical Wnt/Ca<sup>2+</sup>/NFAT signaling has not been examined. Frizzled receptors are known to transduce signals that lead to activation of  $\beta$ -catenin, and knockdown of  $\beta$ -catenin has previously been shown to sensitize CML cells to imatinib (Coluccia et al., 2007). Indeed, we also found that  $\beta$ -catenin knockdown decreased viability of K562 CML cells treated with imatinib, although not nearly to the same extent as knockdown of FZD-8 (Figure S2). Moreover, knockdown of FZD-8 did not affect levels of  $\beta$ -catenin protein in the nucleus or its transcriptional activity (Figure S2), inconsistent with a role for FZD-8 in signaling through the canonical pathway. Given that so many potential mediators of Wnt/Ca<sup>2+</sup>/NFAT signaling were identified in the screen, we wanted to determine whether knockdown of FZD-8 altered the activity of NFAT. Therefore, K562 cells expressing shA, shB, or control shRNA were transduced with an NFAT reporter construct that contains tandem NFAT binding sites derived from the IL-4 promoter fused to luciferase (Braz et al., 2003). Luciferase activity was severely impaired in shB cells relative to control cells (Figure 1D), and this was rescued by treatment with the calcium ionophore ionomycin suggesting that FZD-8 acts upstream of intracellular Ca<sup>2+</sup> release, consistent with a role for FZD-8 in mediating Wnt/Ca<sup>2+</sup>/NFAT pathway signaling.

**Table 1. Potential Wnt/Ca<sup>2+</sup>/NFAT Pathway Genes Identified as SLIMs**


RefSeq ID	Mean FC	Hgnc Symbol	Description	Number of ShRNAs
NM_005438	-183.41	FOSL1	Fos-related antigen 1 (Fra-1)	1
NM_006257	-154.91	PRKCQ	Protein kinase C theta type	2
NM_031866	-146.08	FZD8	Frizzled-8 precursor	3
NM_172084	-133.08	CAMK2B	Calcium/calmodulin-dependent protein kinase type II beta	2
NM_004430	-131.92	EGR3	Early growth response protein 3	2
NM_000589	-106.66	IL4	Interleukin-4 precursor	2
NM_002751	-54.56	MAPK11	Mitogen-activated protein kinase 11 (p38 beta MAPK)	1
NM_006924	-45.85	SFRP4	Secreted frizzled-related protein 4 precursor	1
NM_000880	-45.53	IL7	Interleukin-7 precursor	1
NM_000964	-44.96	RARA	Retinoic acid receptor alpha	2
NM_021132	-34.12	PPP3CB	Calmodulin-dependent calcineurin A subunit beta	1
NM_182734	-31.48	PLCB1	Phospholipase C- beta-1	1
NM_006888	-31.30	CALM1	Calmodulin (CaM)	2
NM_006204	-30.17	PDE6C	cGMP phosphodiesterase 6C	1
NM_003392	-24.94	WNT5A	Wingless-type MMTV integration site family, member 5A	1
NM_005064	-22.99	CCL23	C-C motif chemokine 23 precursor	2
NM_005822	-22.81	RCAN2	Calcipressin-2 (regulator of calcineurin 2)	1
NM_172387	-19.10	NFATC1	Nuclear factor of activated T cells, cytoplasmic 1	1
NM_002958	-16.78	RYK	RYK receptor-like tyrosine kinase	1
NM_019854	-15.79	PRMT8	Protein arginine N-methyltransferase 8	1
NM_006205	-14.95	PDE6H	cGMP phosphodiesterase 6H	1
NM_004414	-13.32	RCAN1	Calcipressin-1 (regulator of calcineurin 1)	1
NM_001466	-12.21	FZD2	Frizzled-2 precursor	1
NM_001222	-12.18	CAMK2G	Calcium/calmodulin-dependent protein kinase type II gamma	1
NM_032815	-12.15	NFATC2IP	NFATc2-interacting protein	1
NM_000944	-11.77	PPP3CA	Calmodulin-dependent calcineurin A subunit alpha isoform	1

Genes are listed in ascending order based on the fold-change of corresponding shRNAs. For genes identified by more than one shRNA, the most negative fold change is shown. See also [Tables S1 and S2](#) and [Figure S1](#).

Our screen identified CaMKII  $\beta$  as a SLIM. Thus, we next examined whether inhibition of CaMKII activity with the CaMKII-specific inhibitor KN93 could sensitize CML cells to the effects of imatinib. After 48 hr, the number of viable cells was counted by flow cytometry ([Figures 2A and 2B](#)). Although KN93 had some effect on cell viability by itself, at 5 and 10  $\mu$ M it showed a synergistic effect with imatinib in cell elimination (combination index [CI] values are shown in [Table S3](#)). Remarkably, the combination of 0.1 or 1  $\mu$ M imatinib and 10  $\mu$ M KN93 resulted in near complete cell death. KN93 is known to have off-target effects including the inhibition of calcium and potassium channels ([Gao et al., 2006; Rezazadeh et al., 2006](#)). However, KN92, an analog of KN93 that retains these off-target effects but is inactive toward CaMKII, was ineffective in combination with imatinib ([Figure S3](#)), suggesting that the observed synergism with KN93 is due to CaMKII inhibition. To verify that synergism with KN93 extends to other Bcr-Abl inhibitors, we demonstrated that KN93 effectively synergized with dasatinib in eliminating K562 cells ([Figure 2C](#)). Although CaMKII is known to participate in Wnt/Ca<sup>2+</sup> signaling, CaMKII involvement in regulation of NFAT-dependent transcription has not been established. Thus, K562 cells transduced with the NFAT-luciferase reporter were treated with KN93 for 16 hr and luciferase activity was assayed. KN93 treat-

ment caused a dose-dependent reduction in NFAT reporter activity ([Figure 2D](#)), especially in the context of ionomycin-stimulated cells (6- to 7-fold inhibition), consistent with CaMKII acting downstream of intracellular calcium release.

Given that our results demonstrated a compelling correlation between impaired NFAT activity and sensitivity of CML cells to Bcr-Abl inhibition, we next focused on calcineurin, an essential regulator of NFAT whose activity is required for the nuclear translocation of NFAT. Calcineurin is an attractive therapeutic target because its activity can be effectively inhibited by both tacrolimus and cyclosporin A (CsA), two drugs that have been in clinical use for many years as immunosuppressants. We first utilized K562 cells to determine if calcineurin inhibition by CsA enhances CML cell killing by imatinib. K562 cells were treated with combinations of CsA and imatinib for 72 hr. The doses of CsA tested (1–5  $\mu$ M) are clinically relevant because patients achieve peak serum concentrations between 1 and 2  $\mu$ M with a standard dosing of CsA used as an immunosuppressant for organ transplantation ([Halloran et al., 1999](#)). Although CsA treatment alone had only a moderate effect on cell number, a dramatic effect on viability was obvious upon combined treatment with CsA and imatinib, with 2.5 and 5  $\mu$ M CsA causing near complete cell death when combined with either 0.1 or 1  $\mu$ M imatinib



**Figure 2. Inhibition of CaMKII Sensitizes CML Cells to Bcr-Abl Inhibition and Impairs NFAT Activity**

(A and B) K562 cells were treated with imatinib and KN93 alone or in combination as indicated (increasing KN93 concentrations of 0, 2, 5, and 10 μM are indicated by the triangles) for 48 hr and viable cells (based on PI exclusion) were counted by flow cytometry (A). Values were normalized to untreated (control) cells and graphed. Representative flow profiles (side scatter versus forward scatter) from these experiments are shown in (B). The “cell” gate was defined based on the scatter profile of untreated viable K562 cells (upper left panel). PI<sup>+</sup> cells are colored in red and PI<sup>-</sup> in violet.


(C) K562 cells were treated with dasatinib and KN93 as in (A) for 48 hr and viable cells were counted.

(D) K562 cells were infected with an NFAT-luciferase reporter. After 32 hr, the cells were treated with the indicated concentrations of KN93 alone or together with ionomycin at 1 μg/ml for 16 hr after which cells were harvested and assayed for luciferase activity. Error bars represent ± SD. See also Figure S3.

(Figure 3A; CI values are shown in Table S3 and representative flow profiles in Figure S4A). The mechanism by which CsA enhances imatinib-mediated cell death appears to be by enhancement of apoptosis, as indicated by a dramatic increase in sub-G<sub>1</sub> DNA content when the two drugs were combined (Figure S4B). CsA also sensitized K562 cells to the Bcr-Abl inhibitor dasatinib (Figure 3B), and thus, as with KN93, the effects of CsA are not unique to imatinib. Reporter assays verified that CsA caused a dose-dependent decrease in NFAT-driven transcription in both unstimulated and ionomycin-stimulated K562 cells (Figure 3C). Importantly, imatinib had no influence on NFAT activity in these cells (Figure S4C). These results suggest that calcineurin inhibition cooperates with Bcr-Abl inhibition to eliminate CML cells.

In addition to calcineurin, CsA is also known to inhibit p-glycoprotein (MDR1), a drug efflux pump that has been proposed to

contribute to imatinib-resistance in CML (Illmer et al., 2004). Thus, the effect of CsA, or perhaps even KN93, could potentially be due to prevention of imatinib efflux from cells, leading to improved Bcr-Abl inhibition. To examine this possibility, we treated K562 cells with imatinib and CsA or KN93, alone or in combination, for 24 hr and subjected them to western blot analysis for tyrosine-phosphorylated forms of known Bcr-Abl substrates including CrkL, STAT5, and Bcr-Abl itself, in addition to global tyrosine phosphorylation. Imatinib effectively inhibited tyrosine phosphorylation of all examined Bcr-Abl substrates (Figure 3D) to varying degrees, and global tyrosine phosphorylation was also affected. However, cotreatment with CsA or KN93 did not enhance this inhibition, inconsistent with roles for CsA or KN93 in increasing intracellular imatinib concentrations. Furthermore, qPCR analysis failed to detect expression of MDR1 in K562 cells, whereas its expression was easily detectable in



**Figure 3. Inhibition of Calcineurin-NFAT by CsA Sensitizes Ph<sup>+</sup> Leukemia Cells to Bcr-Abl Inhibition**

(A) K562 cells were treated with imatinib and CsA alone or in combination as indicated (increasing CsA concentrations of 0, 1, 2.5, and 5  $\mu$ M are indicated by the triangles) for 72 hr and viable cells were counted by flow cytometry.  
 (B) K562 cells were treated with dasatinib and CsA as in (A) for 48 hr and viable cells were counted.  
 (C) K562 cells were infected with an NFAT-luciferase reporter. After 32 hr, the cells were treated with the indicated concentrations of CsA alone or together with ionomycin at 1  $\mu$ g/ml for 16 hr, after which cells were harvested and assayed for luciferase activity.  
 (D) K562 cells were treated with imatinib and CsA as indicated. After 24 hr, the cells were harvested and lysates subjected to western blot analysis for phosphorylated (p) Bcr-Abl, CrkL, STAT5, and total phosphotyrosine or EIF-4E (loading control).  
 (E) KBM7 CML cells were treated with imatinib and CsA as in (A) for 48 hr and viable cells were counted.  
 (F) SUP-B15 Ph<sup>+</sup> ALL cells were treated with imatinib and CsA as in (A) for 72 hr and viable cells were counted. Error bars represent  $\pm$  SD. See also Figure S4.


AML cell lines (data not shown). Thus, the effects of CsA and KN93 on K562 cell viability are not attributable to decreased imatinib efflux through inhibition of MDR1.

The effects of the combination of CsA and imatinib on the viability of a different CML cell line, KBM7, were then assessed (Figure 3E). CsA at 2.5 and 5  $\mu$ M showed synergistic elimination of KBM7 cells in combination with 0.05  $\mu$ M imatinib. Upon drug removal and growth for 3 days, a synergistic effect of the drug combination on long-term viability was evident (Figure S4D). Given the effectiveness of CsA combined with imatinib in killing CML cells, we tested whether the same might also apply to Ph<sup>+</sup> ALL cells, which are known to be more refractory to Bcr-Abl inhibition. We utilized SUP-B15 cells, a cell line established from a patient with Ph<sup>+</sup> B cell ALL. Although neither CsA nor imatinib had a severe effect, the combination caused synergistic cell killing (Figure 3F). These results suggest that calcineurin-NFAT is a promising therapeutic target for CML and Ph<sup>+</sup> ALL.

To determine whether the synergism observed with imatinib and CsA in cell lines extends to primary human tumors, we treated CD34<sup>+</sup> cells isolated from bone marrow of two patients with CML in chronic phase (CP) with imatinib and/or CsA in

colony-forming assays. CsA synergized with imatinib in suppressing colony formation at all doses of imatinib tested in the "Patient 1" sample and at 2  $\mu$ M IM in the "Patient 2" sample (Figure 4A; CI values, Table S3). CsA also cooperated with imatinib in inhibiting proliferation of cells from 2 additional CP CML samples as measured by an MTS assay (Figure S5). Thus, CsA is effective at sensitizing primary human Ph<sup>+</sup> leukemia cells to the effects of Bcr-Abl inhibition.

A fraction of CML patients who initially respond to imatinib develop resistance through mutations in Bcr-Abl that impair imatinib binding. The three most common mutations observed in patients are T315I, E255K, and M351T, with the latter two Bcr-Abl mutants retaining partial sensitivity to imatinib. We have shown that CsA synergizes with imatinib at a concentration that only partially inhibits Bcr-Abl (0.1  $\mu$ M imatinib). To test whether CsA can sensitize cells that express mutated Bcr-Abl to the effects of imatinib, Ba/F3 murine pro-B cells were stably transduced with empty vector, native Bcr-Abl, or Bcr-Abl with M351T or E255K mutations. As shown in Figure 4B, Ba/F3 cells without Bcr-Abl ("Vec") were unaffected by imatinib at 0.1  $\mu$ M, and CsA at 5  $\mu$ M had only a moderate effect on viability.



**Figure 4. CsA Sensitizes Primary CML Cells and Cells with Imatinib-Resistant Forms of Bcr-Abl to Imatinib**

(A) Colony formation assays were performed on CD34<sup>+</sup> cells purified from bone marrow of two patients with chronic phase CML in the presence of imatinib and/or cyclosporine at the indicated concentrations (increasing CsA concentrations of 0, 1, 2.5, and 5 μM [patient 1] or 0, 2.5, and 5 μM [patient 2] are indicated by the triangles).

(B) Ba/F3 cells transduced with vector, wild-type Bcr-Abl, or imatinib-resistant mutant forms of Bcr-Abl (M351T or E255K) were treated with imatinib and CsA alone or in combination as indicated (increasing CsA concentrations of 0, 2.5, and 5 μM are indicated by the triangles) for 72 hr and viable cells were counted. Error bars represent ± SD. See also Figure S5.

NFAT nuclear translocation, and/or the phorbol ester PMA, which activates protein kinase C, promoting activation of NFAT cofactor AP-1. K562 cells were treated with PMA and ionomycin alone or in combination for 6 hr followed by treatment with 1 μM imatinib for 48 hr. Treatment with either agent enhanced cell viability and the combination increased viability by 2.5-fold after exposure to imatinib compared to untreated cells (Figure 5A). We verified that NFATc1, identified in our screen as a SLIM, is expressed in CML cells and that its translocation to the nucleus is induced by ionomycin in the presence or absence of PMA (Figure 5B).

To directly assess whether NFAT activation can protect Ph<sup>+</sup> cells from imatinib, we transduced K562 cells with a retro-


virus encoding a constitutively active NFATc1 coexpressed with GFP (Monticelli and Rao, 2002). Of note, in the absence of imatinib treatment, these cells are unable to maintain overexpression of constitutively active NFATc1 (data not shown), suggesting a negative impact on cell growth. However, imatinib treatment selects for cells that express NFATc1 (GFP<sup>+</sup>), resulting in a 4-fold increase in GFP<sup>+</sup> cells relative to untreated cells (transduction efficiency: ~1%) with no effect on cells carrying empty vector (~4% GFP with or without imatinib) (Figure 5C). Selection for constitutive NFAT activity occurred in the presence and absence of CsA, consistent with complete bypass of the need for calcineurin activity. Thus, activation of NFAT can provide a major survival advantage to CML cells upon Bcr-Abl inhibition with imatinib.

### NFAT Signaling Promotes Survival of Leukemia Cells upon Bcr-Abl Inhibition

If CsA sensitizes Bcr-Abl<sup>+</sup> cells to imatinib-induced cell death through inhibition of calcineurin and subsequent inhibition of NFAT, then activation of NFAT should protect cells from imatinib-induced death. NFAT-dependent transcription can be activated by treatment of cells with ionomycin, which elevates levels of intracellular Ca<sup>2+</sup> resulting in activation of calcineurin and

virus encoding a constitutively active NFATc1 coexpressed with GFP (Monticelli and Rao, 2002). Of note, in the absence of imatinib treatment, these cells are unable to maintain overexpression of constitutively active NFATc1 (data not shown), suggesting a negative impact on cell growth. However, imatinib treatment selects for cells that express NFATc1 (GFP<sup>+</sup>), resulting in a 4-fold increase in GFP<sup>+</sup> cells relative to untreated cells (transduction efficiency: ~1%) with no effect on cells carrying empty vector (~4% GFP with or without imatinib) (Figure 5C). Selection for constitutive NFAT activity occurred in the presence and absence of CsA, consistent with complete bypass of the need for calcineurin activity. Thus, activation of NFAT can provide a major survival advantage to CML cells upon Bcr-Abl inhibition with imatinib.

The majority of NFAT transcriptional targets are cytokines, suggesting that NFAT-driven autocrine cytokine production may protect Ph<sup>+</sup> leukemia cells from Bcr-Abl inhibitor-mediated cell death. To probe for NFAT-dependent cytokine production by CML cells, antibody-based cytokine arrays were performed using conditioned media from untreated K562 cells or K562 cells treated with CsA for 24 hr. CsA inhibited the production of



**Figure 5. NFAT Protects CML Cells from Imatinib-Induced Cell Death**

(A) K562 cells were treated with ionomycin (1  $\mu$ g/ml) alone or in combination with PMA (10 ng/ml). After 16 hr, the cells were treated  $\pm$  1  $\mu$ M imatinib for 48 hr as indicated and the number of viable cells was counted.

(B) K562 cells were treated with PMA and/or ionomycin, or CsA for 16 hr and harvested. Whole cells lysates and nuclear extracts were prepared and subjected to western blotting for NFATc1. The nuclear extract blot was stripped and reprobed for lamin C as a loading control.


(C) K562 cells were infected with retrovirus expressing GFP alone or constitutively active NFATc1-GFP. Forty-eight hours after infection, the cells were treated with imatinib at the indicated concentrations and/or CsA (5  $\mu$ M) for 72 hr and the percentages of viable GFP<sup>+</sup> (relative to all viable cells) were determined with flow cytometry. Error bars represent  $\pm$  SD.

several known NFAT-regulated cytokines, most notably IL-2, IL-4, IFN- $\gamma$ , and TNF- $\alpha$ , whereas other secreted factors not known to be NFAT-dependent, such as MMP3, TNFR1 and IL-15, remained mostly unchanged (Figure 6A). To examine whether knockdown of FZD-8 affects cytokine production, consistent with Wnt/Ca<sup>2+</sup> signaling controlling NFAT activity, we subjected K562 cells expressing shA (negative control) and shB (FZD-8 knockdown), described in Figure 2, to cytokine array analysis. Figure 6B shows that FZD-8 knockdown is not the equivalent of universal calcineurin inhibition with CsA, indicating that there is some specificity to FZD-8 signaling. However, several NFAT-dependent cytokines were commonly downregulated upon FZD-8 knockdown, including IL-4 and IFN- $\gamma$ , supporting a role for FZD-8 signaling in regulating NFAT-controlled transcription of a subset of cytokines.

Given that both CsA treatment and FZD-8 knockdown impair its production and that it was identified as a SLIM, IL-4 is a good candidate for a cytokine with a role in maintaining survival of Ph<sup>+</sup> cells upon Bcr-Abl inhibition. We asked whether the IL-4 neutralizing monoclonal antibody 11B11 could sensitize Bcr-Abl-expressing murine Ba/F3 cells to killing by imatinib. Cytokine array analysis confirmed that these cells have IL-4 production that is suppressed by CsA (Figure S6A). Treatment with 11B11 resulted in dramatic dose-dependent cell killing when combined with imatinib, similar to what was observed with CsA treatment (Figure 6C). Thus, IL-4 inhibition is sufficient to sensitize Bcr-Abl<sup>+</sup> cells to imatinib. A monoclonal antibody that neutralizes murine CD4, which is not expressed by B cells, had only minor effects alone or in combination with imatinib (Figure S6B). Addition of exogenous murine IL-4 protected the cells from the effects of imatinib and, in fact, largely reversed the ability of CsA to sensitize the cells to imatinib (Figure 6D). Because IL-4 is a target of NFAT, these results reinforce the conclusion that the observed synergy with CsA and Bcr-Abl inhibitors is due to calcineurin-NFAT inhibition rather than inhibition of MDR1.


#### NFAT Inhibition with CsA Enhances Elimination of Bcr-Abl<sup>+</sup> Leukemia by Dasatinib In Vivo

Finally, we wanted to test whether inhibition of NFAT signaling by CsA could enhance the ability of a Bcr-Abl inhibitor to eliminate Ph<sup>+</sup> leukemia cells in vivo. Transduction of bone marrow from *ARF*<sup>-/-</sup> mice with p185 Bcr-Abl/GFP generates an aggressive B cell acute lymphoblastic leukemia (B-ALL), providing a tractable model that is reflective of human Ph<sup>+</sup> ALL (Williams et al., 2007). The therapeutic response observed with dasatinib in this model mirrors that seen in patients: although dasatinib reduces leukemic burden, a significant number of dasatinib-refractory leukemia cells are maintained and the disease often relapses with resistance mutations in Bcr-Abl (Williams and Sherr, 2008). To test the effects of dasatinib combined with CsA while using this model, we inoculated mice with  $5 \times 10^5$  *ARF*<sup>-/-</sup> p185 B-ALL cells and after 3 days to allow engraftment, we treated mice with vehicle, CsA alone, dasatinib alone, or dasatinib and CsA in combination. An initial experiment, with therapy up to day 96, showed that mice treated with vehicle or with CsA alone succumbed to leukemia on day 10, whereas treatment with dasatinib alone and dasatinib/CsA resulted in 50% and 100% leukemia-free survival, respectively (Figure S7).



**Figure 6. IL-4 Production Is NFAT and FZD-8 Dependent and Protects Ph<sup>+</sup> Cells from Imatinib**

(A) Conditioned media from K562 cells treated  $\pm$  CsA at 5  $\mu\text{M}$  was used for cytokine array analysis. Cytokines that were consistently detectable are labeled. (B) Conditioned media from K562 cells expressing FZD-8 shA (no knockdown) or shB (FZD-8 knockdown) was prepared and used for cytokine array analysis. (C) Ba/F3 cells expressing Bcr-Abl (described in Figure 4) were treated with imatinib and neutralizing IL-4 antibody (11B11) alone or in combination (increasing 11B11 concentrations of 0, 25, 50, and 100  $\mu\text{g}/\text{ml}$  are indicated by the triangles) for 72 hr and viable cells were counted. (D) Ba/F3 cells expressing Bcr-Abl were treated with the indicated concentrations of recombinant murine IL-4 together with 0.1  $\mu\text{M}$  imatinib and/or 5  $\mu\text{M}$  CsA for 72 hr and viable cells were counted. Error bars represent  $\pm$  SD. See also Figure S6.



**Figure 7. CsA Enhances Elimination of Ph<sup>+</sup> ALL Cells by Dasatinib In Vivo**

C57BL/6 mice were inoculated intravenously with  $5 \times 10^5$  *ARF*<sup>-/-</sup> p185 Bcr-Abl/GFP B-ALL cells. After 3 days, groups of mice were treated once daily by oral gavage with vehicle (80 mM citric acid [pH 3.1]; n = 5), CsA (25 mg/kg; n = 5), dasatinib (20 mg/kg; n = 10), or dasatinib and CsA combined (n = 10) up to day 52 postinoculation.

(A) After 3 days of therapy, peripheral blood from all mice was immunostained for B220 and Mac-1 and analyzed by flow cytometry. The percentage of GFP<sup>+</sup> cells in the B-lineage (B220<sup>+</sup>, Mac-1<sup>-</sup>) population was determined and plotted.

(B) Peripheral blood was taken on the indicated days and analyzed as in (A) and plotted over time. The limit of detection of GFP in peripheral blood, based on analyses of blood from control C57BL/6 mice is ~0.1%.

(C) Kaplan-Meier curve showing survival of mice receiving the indicated therapy. Mice were sacrificed when moribund, and all showed clear evidence of leukemia in blood, bone marrow and spleen. See also Figure S7.

In a second in vivo experiment under the same conditions, leukemic burden in the peripheral blood was assessed by flow cytometry after 3 days of therapy. This analysis found that whereas CsA by itself had no significant effect, CsA in combination with dasatinib was far more effective than dasatinib alone at rapid elimination of Bcr-Abl<sup>+</sup> leukemic B cells (GFP<sup>+</sup>, B220<sup>+</sup>, Mac1<sup>-</sup>) from the blood (Figure 7A). Weekly analysis of peripheral blood showed that GFP<sup>+</sup> B cells remained at near undetectable levels in mice receiving dasatinib/CsA, whereas leukemic cells eventually rose to high levels in mice receiving dasatinib alone (Figure 7B). Mice receiving vehicle or CsA alone were moribund and sacrificed on day 10 (Figure 7C). Postmortem analysis showed extensive leukemia in the blood, bone marrow and spleen (not shown). By day 52, eight of ten mice receiving dasatinib alone had succumbed to leukemia and therapy was halted to determine if leukemia had been eradicated in the surviving mice. The two remaining dasatinib-treated mice succumbed to leukemia within 16 days, whereas all ten of the dasatinib/CsA treated mice remained healthy up to day 119, when the experi-

ment was terminated (Figure 7C). Postmortem analysis of these mice revealed no GFP<sup>+</sup> cells in the blood, bone marrow, and spleen, and white blood cell counts were normal (not shown). Thus, under conditions where dasatinib as monotherapy was largely ineffective, adjuvant therapy with CsA resulted in complete eradication of Bcr-Abl<sup>+</sup> leukemia.

Taken together, our data indicate that signaling through the Wnt/Ca<sup>2+</sup>/NFAT pathway plays a role in maintaining survival of Ph<sup>+</sup> leukemia cells upon Bcr-Abl inhibition and suggests that targeting this pathway in tandem with Bcr-Abl represents an effective therapeutic strategy for treatment of CML and Ph<sup>+</sup> ALL.

## DISCUSSION

Although the success of imatinib in patients with chronic phase CML has revolutionized the treatment of this disease, relapses remain common among patients with advanced CML or Ph<sup>+</sup> ALL, and high failure rates persist with second-line dasatinib and nilotinib therapy (Milone and Enrico, 2009; Quintas-Cardama

et al., 2007). Similar poor response rates are observed with tyrosine kinase inhibitor-based targeted therapy in other types of cancer, which is likely due to the increased genetic complexity of these diseases. Because imatinib therapy has rarely proven to be curative, eradication of Ph<sup>+</sup> leukemias will probably require targeting other gene products in addition to Bcr-Abl.

We applied a large-scale RNAi screening approach to identify genetic pathways that could sensitize blast crisis CML cells to Bcr-Abl inhibition by imatinib. Our screen identified numerous components of a noncanonical Wnt/Ca<sup>2+</sup>/NFAT pathway as being synthetic lethal with imatinib, suggesting this pathway plays a role in maintenance of Bcr-Abl<sup>+</sup> leukemia cells despite Bcr-Abl inhibition. These studies highlight the strength of an unbiased synthetic lethal screen: the Wnt/Ca<sup>2+</sup> pathway has not previously been implicated in CML or Ph<sup>+</sup> ALL pathogenesis, and analyses of gene expression changes that accompany CML progression to advanced phases does not reveal significantly altered expression of this pathway during CML evolution (Radich et al., 2006). A pathway does not necessarily need to be differentially expressed or mutationally deregulated in a cancer to contribute to resistance to a therapy that the cancer did not evolve to endure. An unbiased screen provides a unique opportunity to uncover such pathways.

The Wnt/Ca<sup>2+</sup>/NFAT pathway is largely uncharacterized in mammalian cells, with most studies performed in *Xenopus* and zebrafish, and its role in human cancer remains controversial. Some studies support a role for noncanonical Wnt signaling as tumor-suppressive, while others indicate a role in promoting tumorigenesis (reviewed in Pukrop and Binder, 2008). Our data strongly support a role for the Wnt receptor FZD-8 as a mediator of Wnt/Ca<sup>2+</sup>/NFAT signaling in CML, given that FZD-8 knock-down causes impaired NFAT activity and impaired production of NFAT-regulated cytokines. FZD-8 is a poorly studied receptor that has not previously been shown to be involved in Wnt/Ca<sup>2+</sup> signaling. Ectopic overexpression studies showed that FZD-8 is capable of activating  $\beta$ -catenin-dependent signaling when co-expressed with the canonical coreceptor LRP6 (Liu et al., 2005). However, studies performed in *Xenopus* implicate FZD-8 in  $\beta$ -catenin-independent Wnt signaling (Wallingford et al., 2001). Whether a given FZD receptor signals through canonical or noncanonical pathways may be dependent on what coreceptor is utilized (Cadigan and Liu, 2006).

The Wnt/Ca<sup>2+</sup>/NFAT pathway has multiple branches that lead to activation of PDE, CaMKII, calcineurin and PKC. Given that these enzymes are not known to have shared substrates, it was somewhat surprising that all components of this pathway were identified in our screen. However, multiple components of this pathway can converge on activation of NFAT. We provide evidence that inhibition of FZD-8, CaMKII and calcineurin all impair NFAT activity, which correlates with an increased sensitivity to imatinib. While calcineurin is known to control nuclear translocation of NFAT, the precise role of CaMKII in NFAT activation is less clear. CaMKII has been shown to activate the NFAT-cooperative transcription factor NF- $\kappa$ B in T cells through direct phosphorylation of CARMA1 (Ishiguro et al., 2006). Exactly how CaMKII and other components of this pathway impinge upon NFAT-dependent transcription in Ph<sup>+</sup> leukemia cells remains to be established. Nonetheless, our data strongly argue that NFAT plays a critical role in survival of Ph<sup>+</sup> leukemia cells

upon Bcr-Abl inhibition. This role is best evidenced by our findings that overexpression of constitutively active NFATc1 protects CML cells from imatinib-mediated killing and that CsA sensitizes multiple types of Ph<sup>+</sup> cells to Bcr-Abl inhibition. In light of recent studies implicating calcineurin-NFAT signaling in survival of T cell acute lymphoblastic leukemias (Medyouf et al., 2007), our studies support a perhaps underappreciated role of NFAT in hematopoietic and other types of cancer, since NFAT activation is implicated in tumors of epithelial cell origin as well (Medyouf and Ghysdael, 2008).

Much of the data presented in this report relies on calcineurin-NFAT inhibition by CsA. Given the importance of NFAT for T cell development and function, CsA is commonly utilized in the clinic as an effective immunosuppressive agent after organ transplantation. However, CsA is also known to inhibit p-glycoprotein encoded by the multiple drug resistance gene *MDR1*. Yokota et al. tested INNO-406, an experimental Bcr-Abl inhibitor, in combination with CsA in a mouse model of Ph<sup>+</sup> CNS leukemia where it enhanced INNO-406-mediated elimination of Bcr-Abl-expressing Ba/F3 cells from the brain (Yokota et al., 2007). Their explanation of these results was that CsA acts as a p-glycoprotein inhibitor to decrease efflux of INNO-406 at the blood-brain barrier, although CsA only moderately enhanced INNO-406 levels in the brain. Based on our data, we would argue that their observed effects are more likely due to CsA-mediated calcineurin inhibition synergizing with Bcr-Abl inhibition. In this study, we found no significant effect of CsA on the Bcr-Abl inhibitory activity of imatinib, inconsistent with a role for p-glycoprotein in efflux of imatinib from CML cells. This contention is further supported by the observations that MDR1 deletion does not enhance sensitivity of CML cells to imatinib in vivo (Zong et al., 2005) and artificial overexpression of p-glycoprotein is necessary to enhance imatinib efflux in K562 cells (Illmer et al., 2004).

Our data support a scenario whereby enhanced NFAT activity in Ph<sup>+</sup> cells, mediated by noncanonical Wnt/Ca<sup>2+</sup> signaling, increases autocrine NFAT-dependent cytokine production that provides compensatory survival signaling upon exposure to imatinib. Cytokine signaling is increasingly found to have roles in multiple types of leukemia (Van Etten, 2007), and the noncanonical ligand Wnt5a has been shown to play a role in upregulation of multiple cytokines in hematopoietic cells (Blumenthal et al., 2006; Pereira et al., 2008). We found that IL-4 was commonly downregulated by both FZD-8 and calcineurin-NFAT inhibition, which sensitized Ph<sup>+</sup> leukemia cells to Bcr-Abl inhibition. It is intriguing that autocrine IL-4 production was recently shown to maintain survival of colon cancer stem cells upon treatment with chemotherapeutics (Francipane et al., 2008; Todaro et al., 2007), implicating IL-4 signaling as a general mediator of cell survival in the face of therapeutic stress. Furthermore, deletion of the cytokine receptor common  $\gamma$  chain, through which IL-4 signals, restores the sensitivity of imatinib-refractory Bcr-Abl<sup>+</sup> *ARF*<sup>-/-</sup> ALL cells to imatinib in vivo (Williams et al., 2007). In vivo, stromal cells are a likely source of pro-survival cytokines for leukemia cells. However, given that cytokine gene transcription is often NFAT dependent, inhibiting calcineurin-NFAT should also severely impair cytokine-mediated survival signaling coming from paracrine sources.

The possibility that pro-survival cues might come from the environment of Ph<sup>+</sup> leukemia cells necessitated the testing of

a Bcr-Abl inhibitor in combination with CsA in an in vivo model of Ph<sup>+</sup> leukemia. We chose to test our therapeutic approach in a model of Ph<sup>+</sup> ALL, because this disease is refractory to therapy with Bcr-Abl inhibitors alone. Treatment of mice bearing Bcr-Abl<sup>+</sup> ARF<sup>-/-</sup> ALL cells with dasatinib has been shown to be ineffective in completely eliminating leukemia cells, resulting in the rapid appearance of dasatinib resistance (Williams and Sherr, 2008). Our in vivo results show that dasatinib combined with CsA therapy can be quite successful in eradication of Ph<sup>+</sup> leukemia that is refractory to dasatinib therapy alone. These results could have important implications for improving clinical responses to Bcr-Abl inhibitors in Ph<sup>+</sup> ALL and possibly advanced CML.

The results presented in this report strongly support the therapeutic strategy of combining Bcr-Abl inhibition with inhibition of NFAT by CsA or other NFAT-inhibitory approaches. Given that CsA has long been in clinical use, its pharmacodynamics and side effects are well understood. Thus, clinical trials exploring the efficacy of CsA combined with Bcr-Abl inhibitors for the treatment of Bcr-Abl inhibitor-refractory Ph<sup>+</sup> leukemias may be warranted. The therapeutic efficacy of inhibiting specific NFAT targets, such as IL-4, also deserves exploration. Finally, our synthetic lethal RNAi-based screen, which allowed for the rapid identification of adjuvant drug targets in Bcr-Abl<sup>+</sup> leukemia, may serve as an efficient model for the discovery of combination therapies for the treatment of various other types of cancer.

## EXPERIMENTAL PROCEDURES

### ShRNA Screen and Analysis

A total of  $1 \times 10^7$  K562 cells were transduced with  $1 \times 10^6$  ifu of the lentiviral human 50K shRNA library (GeneNet, SBI) using standard methods. Two days after infection, cells were subjected to selection in puromycin (2.5  $\mu$ g/ml) for a period of 2 weeks. The cells were then divided into six groups of  $1 \times 10^7$  cells: three were left untreated, and the other three were treated with imatinib at 1  $\mu$ M for 72 hr and were cultured for an additional week. Total RNA was isolated from each group using Trizol reagent (Invitrogen) and reverse transcribed with M-MLV reverse transcriptase (Epicenter). shRNA sequences were PCR amplified and labeled with biotin according to the manufacturer's instructions. Then, 15  $\mu$ g biotin-labeled PCR products were used for hybridization to microarrays (Affymetrix, HG-U133+ 2.0) and analysis of signal intensities was performed with GeneNet software (SBI). See the Supplemental Information for details of the data normalization and determination of significant changes.

### Cell Culture and Generation of Cell Lines

K562 and KBM7 cells (a gift from M. Beran, MD Anderson) were cultured in Iscove's modified Dulbecco's medium/10% fetal bovine serum (FBS). For generation of shRNA-expressing cell lines, lentivirus production from pLKO.1 constructs and transduction were performed as described previously (Porter and DeGregori, 2008) and cells were selected and maintained in puromycin (2.5  $\mu$ g/ml). SUP-B15 cells were cultured in RPMI 1640 medium/20% FBS with 5mM  $\beta$ -mercaptoethanol. Ba/F3 cells were cultured in RPMI 1640 medium/10% FBS and 15% WEHI3 conditioned medium (WCM). Ba/F3 cell lines expressing Bcr-Abl and mutated derivatives (gifts of B. Deininger, OHSU) were generated by retroviral transduction using MSCV-ires-GFP constructs as previously described (Marusyk et al., 2007); GFP<sup>+</sup> cells were sorted and maintained in media lacking WCM. Bcr-Abl<sup>+</sup> ARF<sup>-/-</sup> ALL cells were generated as previously described (Williams et al., 2007) and were cultured in RPMI 1640 medium/10% FBS and 2x L-glutamine prior to inoculation into mice.

### Quantitative Real-Time PCR

Quantitative real-time PCR was performed with the TaqMan method as described previously (Shapiro et al., 2006). Primer and probe sequences are provided in the Supplemental Information.

### Cell Viability Assays

Cells were seeded at  $1 \times 10^5$ /ml in triplicate wells of 24-well tissue culture plates. Where indicated, the cells (immediately after seeding) were treated with drug for a period of 48–72 hr. After or during treatment, a sample of cells from each well was stained with PI (10  $\mu$ g/ml) and viable cells (PI<sup>-</sup>) were counted with a flow cytometer (Quanta SC, Beckman Coulter). For some experiments, the number of GFP<sup>+</sup> viable (PI<sup>-</sup>) was counted in the same manner. The results from two independent experiments were combined and plotted with the standard deviation (SD).

### Colony-Forming Assays

A total of  $5 \times 10^4$  CD34<sup>+</sup> cells from primary CP CML samples were plated in 0.9% MethoCult (Stem Cell Technologies) supplemented with 30% FBS, 1% bovine serum albumin, 2 mM L-glutamine and rhIL-3 (100 ng/ml), and in the presence of the indicated drug combinations. Colony numbers were scored 14 days after plating. The frozen nonidentifiable bone marrow patient specimens were obtained with informed consent from the OSU Leukemia Tissue Bank, Columbus OH, and all of the performed experiments were approved by The OSU Institutional Review Board.

### Western Blotting

Nuclear extracts were prepared with the protocol described at [http://www.protocol-online.org/cgi-bin/prot/view\\_cache.cgi?ID=2701](http://www.protocol-online.org/cgi-bin/prot/view_cache.cgi?ID=2701). Preparation of whole cell lysates and western blotting were performed as previously described (Shapiro et al., 2006). Antibodies utilized were anti-NFATc1 (7A6, Santa Cruz), anti-lamin C (636, Santa Cruz), anti- $\beta$ -catenin (clone14, BD Transduction Laboratories), anti- $\alpha$ -tubulin (DM1A; MeoMarkers), and antiphosphotyrosine (4G10; Millipore). Phosphospecific antibodies to c-Abl (#2681), CrkL (#3181) and Stat5 (#9351), and anti-elF4E (#9742) were from Cell Signaling Technology.

### Reporter Assays

K562 cells were coinfecting with 10 infectious units (ifu)/cell of adenovirus containing the 9XNFAT-luciferase reporter plus adenovirus expressing GFP. Forty-eight hours after infection, a sample of cells was analyzed by flow cytometry to determine the number of viable (PI<sup>-</sup>) GFP<sup>+</sup> cells and lysates were subjected to standard firefly luciferase assays (Promega). Luciferase values were normalized to the number of GFP<sup>+</sup> cells. Results shown are from two independent experiments; error bars represent SD.

### Cytokine Assays

Conditioned media was generated by incubating  $2 \times 10^6$  cells in 2 ml low serum (0.2% FBS) media for 24 hr, in the presence or absence of CsA, as indicated. Conditioned media was incubated on antibody-based cytokine arrays (Panomics, Human Array 3.0) for 16 hr at 4°C. Detection was performed according to the manufacturer's instructions. Results are representative of two independent experiments.

### Mice

Female C57BL/6 mice (6–10 weeks old) from the National Cancer Institute were utilized for experiments. Dasatinib was prepared by dissolving in 80 mM citric acid (pH 2.1) daily for oral gavage. Cyclosporin A (Neoral; Novartis) was added directly to vehicle or dasatinib preparation just prior to gavage. All mouse experiments were approved by the University of Colorado Denver IACUC.

### Flow Cytometry Analysis

Flow cytometry was performed as previously described (Porter and DeGregori, 2008). Antibodies utilized for cell surface staining were anti-mouse B220-APC, anti-mouse B220-PE, and anti-mouse Mac1-PE-Cy7 (all from eBioscience). Statistical analysis of results was performed using Prism 4 software (GraphPad). Unpaired two-tailed t tests were used for determining statistical significance between two groups.

### ACCESSION NUMBERS

Microarray data from the screen have been deposited at NCBI GEO under the accession number GSE21499.

## SUPPLEMENTAL INFORMATION

Supplemental Information includes seven figures, three tables, and Supplemental Experimental Procedures and can be found with this article online at doi:10.1016/j.ccr.2010.04.025.

## ACKNOWLEDGMENTS

J.D. is supported by the Leukemia and Lymphoma Society (108692) and the National Cancer Institute (NCI; RO1-CA109657) and M.G. by the Cancer League of Colorado and the NCI (K01-CA133182). D.P. is supported by the NCI (CA095512) and the US Army and CML Research Program (DAMD17-03-1-0184). D.P. is a Scholar of The Leukemia and Lymphoma Society. R.W. is supported by an NIH Cancer Center Support Core Grant (CA-21765), the American Lebanese Syrian Associated Charities, and a Career Development Award from the AACR. We would like to thank Anjana Rao, Jeff Molkenin, Heide Ford, Ulli Bayer, Michael Deininger, and Charles Sherr for providing reagents; Dexiang Gao for statistical analyses; Nidal Boulos for characterization of Arf-null/p185 Bcr-Abl<sup>+</sup> GFP<sup>+</sup> cells; Andriy Marusyk, Christopher Porter, and Richard Gregory for comments on the manuscript; Bifeng Gao and Uma Pugazhenthii of the UC Cancer Center Gene Expression Core; and Karen Helm and Christine Childs of the UC Cancer Center Flow Cytometry Core (supported by NIH grant 2P30-CA46934).

Received: May 8, 2009  
Revised: March 4, 2010  
Accepted: May 4, 2010  
Published: July 12, 2010

## REFERENCES

- Ahumada, A., Slusarski, D.C., Liu, X., Moon, R.T., Malbon, C.C., and Wang, H.Y. (2002). Signaling of rat Frizzled-2 through phosphodiesterase and cyclic GMP. *Science* **298**, 2006–2010.
- Blumenthal, A., Ehlers, S., Lauber, J., Buer, J., Lange, C., Goldmann, T., Heine, H., Brandt, E., and Reiling, N. (2006). The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. *Blood* **108**, 965–973.
- Boise, L.H., Petryniak, B., Mao, X., June, C.H., Wang, C.Y., Lindsten, T., Bravo, R., Kovary, K., Leiden, J.M., and Thompson, C.B. (1993). The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB. *Mol. Cell Biol.* **13**, 1911–1919.
- Braz, J.C., Bueno, O.F., Liang, Q., Wilkins, B.J., Dai, Y.S., Parsons, S., Braunwart, J., Glascock, B.J., Klevitsky, R., Kimball, T.F., et al. (2003). Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. *J. Clin. Invest.* **111**, 1475–1486.
- Cadigan, K.M., and Liu, Y.I. (2006). Wnt signaling: Complexity at the surface. *J. Cell Sci.* **119**, 395–402.
- Coluccia, A.M., Vacca, A., Dunach, M., Mologni, L., Redaelli, S., Bustos, V.H., Benati, D., Pinna, L.A., and Gambacorti-Passerini, C. (2007). Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. *EMBO J.* **26**, 1456–1466.
- Deininger, M., Buchdunger, E., and Druker, B.J. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. *Blood* **105**, 2640–2653.
- Deininger, M.W., Goldman, J.M., and Melo, J.V. (2000). The molecular biology of chronic myeloid leukemia. *Blood* **96**, 3343–3356.
- Faderl, S., Garcia-Manero, G., Thomas, D.A., and Kantarjian, H.M. (2002). Philadelphia chromosome-positive acute lymphoblastic leukemia—current concepts and future perspectives. *Rev. Clin. Exp. Hematol.* **6**, 142–160.
- Francipane, M.G., Alea, M.P., Lombardo, Y., Todaro, M., Medema, J.P., and Stassi, G. (2008). Crucial role of interleukin-4 in the survival of colon cancer stem cells. *Cancer Res.* **68**, 4022–4025.
- Gao, L., Blair, L.A., and Marshall, J. (2006). CaMKII-independent effects of KN93 and its inactive analog KN92: Reversible inhibition of L-type calcium channels. *Biochem. Biophys. Res. Commun.* **345**, 1606–1610.
- Gringhuis, S.I., de Leij, L.F., Verschuren, E.W., Borger, P., and Vellenga, E. (1997). Interleukin-7 upregulates the interleukin-2-gene expression in activated human T lymphocytes at the transcriptional level by enhancing the DNA binding activities of both nuclear factor of activated T cells and activator protein-1. *Blood* **90**, 2690–2700.
- Guo, L., Urban, J.F., Zhu, J., and Paul, W.E. (2008). Elevating calcium in Th2 cells activates multiple pathways to induce IL-4 transcription and mRNA stabilization. *J. Immunol.* **181**, 3984–3993.
- Halloran, P.F., Helms, L.M., Kung, L., and Noujaim, J. (1999). The temporal profile of calcineurin inhibition by cyclosporine in vivo. *Transplantation* **68**, 1356–1361.
- Hodge, M.R., Chun, H.J., Rengarajan, J., Alt, A., Lieberson, R., and Glimcher, L.H. (1996). NF-AT-Driven interleukin-4 transcription potentiated by NIP45. *Science* **274**, 1903–1905.
- Hogan, P.G., Chen, L., Nardone, J., and Rao, A. (2003). Transcriptional regulation by calcium, calcineurin, and NFAT. *Genes Dev.* **17**, 2205–2232.
- Illmer, T., Schaich, M., Platzbecker, U., Freiberg-Richter, J., Oelschlagel, U., von Bonin, M., Pursche, S., Bergemann, T., Ehninger, G., and Schleyer, E. (2004). P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. *Leukemia* **18**, 401–408.
- Ishiguro, K., Green, T., Rapley, J., Wachtel, H., Giallourakis, C., Landry, A., Cao, Z., Lu, N., Takafumi, A., Goto, H., et al. (2006). Ca<sup>2+</sup>/calmodulin-dependent protein kinase II is a modulator of CARMA1-mediated NF-kappaB activation. *Mol. Cell Biol.* **26**, 5497–5508.
- Kim, G.H., Her, J.H., and Han, J.K. (2008). Ryk cooperates with Frizzled 7 to promote Wnt11-mediated endocytosis and is essential for *Xenopus laevis* convergent extension movements. *J. Cell Biol.* **182**, 1073–1082.
- Kuhl, M., Sheldahl, L.C., Malbon, C.C., and Moon, R.T. (2000). Ca<sup>2+</sup>/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in *Xenopus*. *J. Biol. Chem.* **275**, 12701–12711.
- Liu, G., Bafico, A., and Aaronson, S.A. (2005). The mechanism of endogenous receptor activation functionally distinguishes prototype canonical and noncanonical Wnts. *Mol. Cell Biol.* **25**, 3475–3482.
- Liu, Q., Busby, J.C., and Molkenin, J.D. (2009). Interaction between TAK1-TAB1-TAB2 and RCAN1-calcineurin defines a signalling nodal control point. *Nat. Cell Biol.* **11**, 154–161.
- Marusyk, A., Wheeler, L.J., Mathews, C.K., and DeGregori, J. (2007). p53 mediates senescence-like arrest induced by chronic replicational stress. *Mol. Cell Biol.* **27**, 5336–5351.
- Medyouf, H., Alcalde, H., Berthier, C., Guillemin, M.C., dos Santos, N.R., Janin, A., Decaudin, D., de The, H., and Ghysdael, J. (2007). Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. *Nat. Med.* **13**, 736–741.
- Medyouf, H., and Ghysdael, J. (2008). The calcineurin/NFAT signaling pathway: A novel therapeutic target in leukemia and solid tumors. *Cell Cycle* **7**, 297–303.
- Milone, J.H., and Enrico, A. (2009). Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. *Leuk. Lymphoma* **50** (Suppl 2), 9–15.
- Monticelli, S., and Rao, A. (2002). NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription. *Eur. J. Immunol.* **32**, 2971–2978.
- Mowen, K.A., Schurter, B.T., Fathman, J.W., David, M., and Glimcher, L.H. (2004). Arginine methylation of NIP45 modulates cytokine gene expression in effector T lymphocytes. *Mol. Cell* **15**, 559–571.
- Ottmann, O.G., Druker, B.J., Sawyers, C.L., Goldman, J.M., Reiffers, J., Silver, R.T., Tura, S., Fischer, T., Deininger, M.W., Schiffer, C.A., et al. (2002). A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. *Blood* **100**, 1965–1971.
- Pereira, C., Schaer, D.J., Bachli, E.B., Kurrer, M.O., and Schoedon, G. (2008). Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. *Arterioscler. Thromb. Vasc. Biol.* **28**, 504–510.
- Porter, C.C., and DeGregori, J. (2008). Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection. *Blood* **112**, 4466–4474.

- Pukrop, T., and Binder, C. (2008). The complex pathways of Wnt 5a in cancer progression. *J. Mol. Med.* 86, 259–266.
- Quintas-Cardama, A., Kantarjian, H., and Cortes, J. (2007). Flying under the radar: The new wave of BCR-ABL inhibitors. *Nat. Rev. Drug Discov.* 6, 834–848.
- Radich, J.P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., Sawyers, C., Shah, N., Stock, W., Willman, C.L., et al. (2006). Gene expression changes associated with progression and response in chronic myeloid leukemia. *Proc. Natl. Acad. Sci. USA* 103, 2794–2799.
- Rengarajan, J., Mittelstadt, P.R., Mages, H.W., Gerth, A.J., Kroczek, R.A., Ashwell, J.D., and Glimcher, L.H. (2000). Sequential involvement of NFAT and Egr transcription factors in FasL regulation. *Immunity* 12, 293–300.
- Rezazadeh, S., Claydon, T.W., and Fedida, D. (2006). KN-93 (2-[N-(2-hydroxyethyl)-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. *J. Pharmacol. Exp. Ther.* 317, 292–299.
- Rousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J.M., Maarek, O., Blanchet, O., Marit, G., Gluckman, E., Reiffers, J., et al. (2007). Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. *Blood* 109, 58–60.
- Saneyoshi, T., Kume, S., Amasaki, Y., and Mikoshiba, K. (2002). The Wnt/calcium pathway activates NF-AT and promotes ventral cell fate in *Xenopus* embryos. *Nature* 417, 295–299.
- Sattler, M., and Griffin, J.D. (2003). Molecular mechanisms of transformation by the BCR-ABL oncogene. *Semin. Hematol.* 40, 4–10.
- Shapiro, G.S., Van Peurse, C., Ornelles, D.A., Schaack, J., and DeGregori, J. (2006). Recombinant adenoviral vectors can induce expression of p73 via the E4-orf6/7 protein. *J. Virol.* 80, 5349–5360.
- Sheldahl, L.C., Slusarski, D.C., Pandur, P., Miller, J.R., Kuhl, M., and Moon, R.T. (2003). Dishevelled activates Ca<sup>2+</sup> flux, PKC, and CamKII in vertebrate embryos. *J. Cell Biol.* 161, 769–777.
- Shin, Y.H., Lee, G.W., Son, K.N., Lee, S.M., Kang, C.J., Kwon, B.S., and Kim, J. (2007). Promoter analysis of human CC chemokine CCL23 gene in U937 monocytoid cells. *Biochim. Biophys. Acta* 1769, 204–208.
- Si, J., Mueller, L., and Collins, S.J. (2007). CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. *J. Clin. Invest.* 117, 1412–1421.
- Slusarski, D.C., Corces, V.G., and Moon, R.T. (1997). Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. *Nature* 390, 410–413.
- Todaro, M., Alea, M.P., Di Stefano, A.B., Cammareri, P., Vermeulen, L., Iovino, F., Tripodo, C., Russo, A., Gulotta, G., Medema, J.P., et al. (2007). Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. *Cell Stem Cell* 1, 389–402.
- Van Etten, R.A. (2007). Aberrant cytokine signaling in leukemia. *Oncogene* 26, 6738–6749.
- Veeman, M.T., Axelrod, J.D., and Moon, R.T. (2003). A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. *Dev. Cell* 5, 367–377.
- Wallingford, J.B., Vogeli, K.M., and Harland, R.M. (2001). Regulation of convergent extension in *Xenopus* by Wnt5a and Frizzled-8 is independent of the canonical Wnt pathway. *Int. J. Dev. Biol.* 45, 225–227.
- Williams, R.T., den Besten, W., and Sherr, C.J. (2007). Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. *Genes Dev.* 21, 2283–2287.
- Williams, R.T., and Sherr, C.J. (2008). The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias. *Cold Spring Harb. Symp. Quant. Biol.* 73, 461–467.
- Yokota, A., Kimura, S., Masuda, S., Ashihara, E., Kuroda, J., Sato, K., Kamitsuji, Y., Kawata, E., Deguchi, Y., Urasaki, Y., et al. (2007). INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph<sup>+</sup> leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. *Blood* 109, 306–314.
- Zong, Y., Zhou, S., and Sorrentino, B.P. (2005). Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. *Leukemia* 19, 1590–1596.

## Supplemental Information

### Wnt/Ca<sup>2+</sup>/NFAT Signaling Maintains Survival

#### of Ph<sup>+</sup> Leukemia Cells upon Inhibition of Bcr-Abl

Mark A. Gregory, Tzu L. Phang, Paolo Neviani, Francesca Alvarez-Calderon, Christopher A. Eide, Thomas O'Hare, Vadym Zaberezhnyy, Richard T. Williams, Brian J. Druker, Danilo Perrotti, and James DeGregori

#### Supplemental Legends to Tables


**Table S1. Related to Table 1. List of shRNAs targeting SLIM genes.** Listed in alphabetical order based on HGNC symbol. FC; fold-change. Intensity values for a given probe set are provided: plus.1, plus.2 and plus.3 reflect detection of a given shRNA from the three imatinib treated cultures, and minus.1, minus.2 and minus.3 reflect detection of a given shRNA from untreated cultures.

**Table S2. Related to Table 1. Biological functions overrepresented among SLIM genes.** List was generated using Ingenuity Pathways Analysis (Ingenuity Systems).


**Table S3. Related to Figures 2, 3, and 4. Combination index (CI values) for drug combinations tested in cell viability assays.** CI values were calculated using CalcuSyn software (Biosoft). CI values less than 1 correspond to synergistic drug interactions, CI values equal to 1 correspond to additive interactions, and CI values more than 1 correspond to antagonistic interactions.

# Figure S1

## A




## B




**Figure S1. Related to Table 1. Fold-changes in the levels of individual shRNAs after imatinib treatment and biological functions of SLIM genes.** **A)** Mean fold-changes for individual shRNA's were calculated as described in Supplemental Experimental Procedures and plotted versus frequency. The number above each bar shows the exact number of shRNAs that fall into each "bin" representing a range of fold-changes. The bin that includes shRNAs exhibiting no significant change (-5 to +5) would also include shRNAs from the library that were undetectable by the arrays. **B)** The SLIM gene list (Table S1) was analyzed using Ingenuity Pathways Analysis software (Ingenuity Systems). The top ten ranked functional categories identified by this analysis are shown. The  $\log(p\text{-value})$  refers to the significance of the overrepresentation of SLIM genes within a functional category.

# Figure S2




**Figure S2. Related to Figure 1. FZD-8 does not signal through  $\beta$ -catenin.** **A)** K562 cell lines expressing shRNAs targeting FZD-8 (shA and B) or a negative control shRNA were subjected to cell viability analysis: cells were seeded at  $1 \times 10^5$ /ml in triplicate in 24-well tissue culture plates and the number of viable cells (based on PI-exclusion) was counted by flow cytometry at the indicated time points and plotted. **B)** K562 cells were stably transduced with shRNAs targeting  $\beta$ -catenin (CTNNB) or negative control shRNA. Whole cell lysates were prepared and subjected to western blotting for  $\beta$ -catenin. The blot was stripped and reprobed for  $\alpha$ -tubulin as a loading control. **C)** K562 cell lines expressing the indicated shRNA were left untreated or **D)** treated with imatinib mesylate at  $1 \mu\text{M}$  for 72 hr, after which the cells were reseeded in the absence of drug and cultured for an additional 4 days. Viable (PI-excluded) cells were counted at the indicated time points using a flow cytometer. **E)** K562 shRNA-expressing cell lines were left untreated or treated with 10 mM LiCl for 24 hr (LiCl inhibits GSK-3, which leads to stabilization of  $\beta$ -catenin and its translocation to the nucleus). Whole cell lysates and nuclear extracts were prepared and subjected to Western blotting for  $\beta$ -catenin. The blots were stripped and reprobed for  $\alpha$ -tubulin or lamin C as loading controls. **F)** K562 cell lines were transiently cotransfected with the TOP-FLASH luciferase reporter plasmid and pRL-TK (Promega) expressing renilla luciferase. After 24 hr, the cells were harvested and assayed for luciferase activity. TOP-FLASH promoter activity was normalized to renilla luciferase. Error bars  $\pm$  SD.

# Figure S3




**Figure S3. Related to Figure 2. The KN93 analog, KN92, does not effectively sensitize CML cells to imatinib.** K562 cells were seeded at  $1 \times 10^5$  cells/ml in 24-well tissue culture plates. Cells were treated with the indicated concentrations of imatinib and KN92 in triplicate. After 48 hr, the cells were stained with PI and viable (PI-excluded) cells were counted using a flow cytometer; error bars +/- SD.

# Figure S4




**Figure S4. Related to Figure 3. CsA enhances imatinib-induced apoptosis of CML cells and imatinib does not influence NFAT activity.** **A**) Representative flow profiles of K562 CML cells treated with imatinib and/or CsA. Cells were treated as described in the legend to Figure 3A. The “cell” gate was defined based on the scatter profile of untreated viable K562 cells (upper left panel). PI<sup>+</sup> cells are colored in red and PI in violet. **B**) K562 cells were seeded at  $1 \times 10^5$  cells/ml and were left untreated or treated with CsA (5  $\mu\text{M}$ ) and/or imatinib (0.1  $\mu\text{M}$ ) as indicated for 72 hr. The cells were then resuspended in a saponin/propidium iodide solution (25  $\mu\text{g/ml}$  propidium iodide, 0.3 % saponin, 0.1 mM EDTA, and 2 U/ml RNase), incubated overnight at 4 $^{\circ}$  C, and analyzed for sub-G1 peak by flow cytometry. Modfit LT (Verity Software) was used for cell cycle and apoptotic peak modeling. **C**) K562 cells were infected with adenovirus containing the 9XNFAT-luc reporter. Thirty-two hours after infection, the cells were treated with ionomycin (1  $\mu\text{g/ml}$ ) and CsA (5  $\mu\text{M}$ ), imatinib (IM; 1  $\mu\text{M}$ ), or CsA /imatinib for 16 hr as indicated and lysates were subjected to standard firefly luciferase assays. **D**) KBM7 cells were seeded at  $1 \times 10^5$  cells/ml in 24-well tissue culture plates. The cells were treated with the indicated concentrations of imatinib and 0, 1, 2.5 or 5  $\mu\text{M}$  of CsA (increasing CsA concentrations indicated by blue triangles) in triplicate wells. After 72 hr, the cells were removed from the drugs, replated, and grown for an additional 72 hr. Viable (PI-excluded) cells were counted using a flow cytometer and the numbers plotted. Error bars +/- SD.

## Figure S5




**Figure S5. Related to Figure 4. CsA cooperates with imatinib in inhibiting proliferation of primary CML cells.** Mononuclear cells taken from the bone marrow of 2 patients with newly diagnosed chronic phase CML (CP New Dx) were treated with imatinib and/or CsA for 72 hr at the indicated concentrations and were subjected to an MTS-based proliferation assay; error bars +/- SD.

# Figure S6



**Figure S6. Related to Figure 6. CsA inhibits IL-4 production in Bcr-Abl<sup>+</sup> Ba/F3 and an antibody against CD4 does not effectively sensitize these cells to imatinib.** **A)** Media was conditioned by incubating  $2 \times 10^6$  Ba/F3 p210 Bcr-Abl cells in 2 ml of low serum media (0.2% FBS) in the presence or absence of 5  $\mu$ M CsA for 24 hr. The conditioned media was incubated overnight at 4°C on antibody based cytokine arrays (RayBio Mouse Cytokine Antibody Array 1, Ray Biotech) followed by ECL-based detection according to the manufacturer's instructions. **B)** Bcr-Abl<sup>+</sup> Ba/F3 cells were treated with imatinib and neutralizing CD4 monoclonal antibody ( $\alpha$ -CD4) alone or in combination as indicated (increasing  $\alpha$ -CD4 concentrations of 0, 25, 50, and 100  $\mu$ g/ml are indicated by the triangles) for 72 hr and viable cells were counted; error bars +/- SD.

# Figure S7



**Figure S7. Related to Figure 7. CsA combined with dasatinib improves survival in a mouse model of Ph<sup>+</sup>ALL.** C57Bl/6 were inoculated intravenously with  $5 \times 10^5$  Arf<sup>-/-</sup> p185 Bcr-Abl<sup>+</sup> B-ALL cells. After 3 days, groups of mice were treated once daily by oral gavage with vehicle, CsA (25mg/kg), dasatinib (20mg/kg) or both drugs for a period of 96 days. Kaplan-Meier curve shows overall survival. Surviving mice were sacrificed on day 146. Post-mortem analyses showed no leukemia (GFP<sup>+</sup>) cells in the blood, bone marrow, or spleen.

## Supplemental Experimental Procedures

### *Data analyses for shRNA screen*

The intensity values from microarrays were first normalized by computing a mean value for each chip, and a global mean was then selected from the minimum of all the means. The normalization factors for each chip were then computed by dividing each individual mean by the global mean. The normalization process was performed by multiplying the intensity values for each chip by the respective normalization factor. 21,664 total probes were detectable (> 1.5-fold) above background. We then compared each “imatinib” chip to each “untreated” chip to compute the fold change for each probe. Given this configuration, a combination of 9 fold changes for each probe was produced. Linear models and empirical Bayes methods were used for assessing differential expression as described in Smyth, G. K. (2004). The probe-wise sample variances were shrunk towards a common value and the degrees of freedom for the individual variances were augmented. The (FDR) adjusted p-values were reported. Significant probes are defined by having at least 6 of the 9 fold changes greater than the percentile threshold and a p-value of <0.05. Since the shRNA library manufacturer used duplicated probe IDs to represent probes selected from similar gene regions, these IDs were renamed by post-fixing a unique number. Using the NCBI “blastall” program, the proprietary probe IDs were then translated into meaningful annotation by aligning the corresponding short sequence against the NCBI RefSeq database. Finally, gene information was extracted using the Biomart Bioconductor package (Ensembl).

### *Reagents*

KN92 and KN93 were obtained from Calbiochem. PMA (Phorbol 12-Myristate 13-Acetate) and ionomycin were obtained from Sigma, and cyclosporine, in the form of Neoral, was from Novartis. Anti-IL-4 was produced and purified from the 11B11 hybridoma using standard methods. Recombinant murine IL-4 was from R&D Systems.

### *Plasmids*

pLKO.1 lentiviral constructs containing shRNA targeting FZD-8 (“shA”: clone ID TRC N0000008348, and “shB”: clone ID TRC N0000008351) and an shRNA to SFRS1 that is non-targeting (“negative control”: clone ID TRC N0000010592) were purchased from Open Biosystems. Adenoviral 9xNFAT-luc reporter was obtained from Jeff Molkentin (Cincinnati Children's Hospital Medical Center). caFNATc1/GFP construct was obtained from Anjana Rao (Harvard Medical School). Mouse stem cell virus (MSCV)-internal ribosome entry site (IRES)-green fluorescent protein (GFP) constructs expressing native Bcr-Abl, M351T, and E255K were obtained from Michael Deininger (Oregon Health & Science University). TOP-FLASH-luc reporter was obtained from Heide Ford (UC Denver).

### *Real-time PCR primers and probe*

The following primer/probe sequences were used for FZD-8 detection. FWD: 5'-CAAGACAGGCCAGATCGCTAA - 3'; REV: 5'- GCTCGTCCTGGCTGAAAAAG - 3' and the probe 6FAM-CGCGCTGCCCTGCCACAAC -TAMRA. The TaqMan probe was purchased from Applied Biosystems 5' labeled with 6-carboxyfluorescein (FAM) and 3'-labeled with 6-carboxy-tetramethylrhodamine (TAMRA). Quantities of FZD8 in test samples were normalized to the corresponding 18s rRNA (PE ABI, P/N 4308310).

### *MTS assays*

Primary mononuclear cells from newly diagnosed CML patients were plated ( $5 \times 10^4$ /well) in quadruplicate in complete media (RPMI medium 1640 supplemented with 10% FCS and 100  $\mu$ M  $\beta$ -mercaptoethanol) in the presence of cyclosporin A (1, 2.5, 5  $\mu$ M) or imatinib (1  $\mu$ M)

either alone or in dual-combinations. Cells were incubated at 37 °C for 72 h and analyzed using a methanethiosulfonate-based viability assay (CellTiter96 Aqueous One solution reagent; Promega). Mean values for each treatment condition were normalized to that of untreated cells, and error bars +/- S.E.M. Samples were obtained with informed consent and under the approval of the OHSU Institutional Review Board.